Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 35

1.
2.

Generation of Potent Anti-Vascular Endothelial Growth Factor Neutralizing Antibodies from Mouse Phage Display Library for Cancer Therapy.

Lai YD, Wu YY, Tsai YJ, Tsai YS, Lin YY, Lai SL, Huang CY, Lok YY, Hu CY, Lai JS.

Int J Mol Sci. 2016 Feb 5;17(2):214. doi: 10.3390/ijms17020214.

3.

Steroid Receptor Coactivator-3 (SRC-3/AIB1) as a Novel Therapeutic Target in Triple Negative Breast Cancer and Its Inhibition with a Phospho-Bufalin Prodrug.

Song X, Zhang C, Zhao M, Chen H, Liu X, Chen J, Lonard DM, Qin L, Xu J, Wang X, Li F, O'Malley BW, Wang J.

PLoS One. 2015 Oct 2;10(10):e0140011. doi: 10.1371/journal.pone.0140011.

4.
5.

Effect of Blocking of Neuropeptide Y Y2 Receptor on Tumor Angiogenesis and Progression in Normal and Diet-Induced Obese C57BL/6 Mice.

Alasvand M, Rashidi B, Javanmard SH, Akhavan MM, Khazaei M.

Glob J Health Sci. 2015 Mar 26;7(7 Spec No):69-78. doi: 10.5539/gjhs.v7n7p69.

6.

High Density Lipoprotein Nanoparticles Deliver RNAi to Endothelial Cells to Inhibit Angiogenesis.

Tripathy S, Vinokour E, McMahon KM, Volpert OV, Thaxton CS.

Part Part Syst Charact. 2014 Nov 1;31(11):1141-1150.

7.

Vascular channels formed by subpopulations of PECAM1+ melanoma cells.

Dunleavey JM, Xiao L, Thompson J, Kim MM, Shields JM, Shelton SE, Irvin DM, Brings VE, Ollila DW, Brekken RA, Dayton PA, Melero-Martin JM, Dudley AC.

Nat Commun. 2014 Oct 22;5:5200. doi: 10.1038/ncomms6200.

8.

Immune effects of bevacizumab: killing two birds with one stone.

Elamin YY, Rafee S, Toomey S, Hennessy BT.

Cancer Microenviron. 2015 Apr;8(1):15-21. doi: 10.1007/s12307-014-0160-8.

9.

The proliferation of malignant melanoma cells could be inhibited by ranibizumab via antagonizing VEGF through VEGFR1.

Li J, Cui Y, Wang Q, Guo D, Pan X, Wang X, Bi H, Chen W, Liu Z, Zhao S.

Mol Vis. 2014 May 13;20:649-60.

10.

Metabotropic glutamate receptor-1 as a novel target for the antiangiogenic treatment of breast cancer.

Speyer CL, Hachem AH, Assi AA, Johnson JS, DeVries JA, Gorski DH.

PLoS One. 2014 Mar 14;9(3):e88830. doi: 10.1371/journal.pone.0088830.

11.
12.

VEGF and pleiotrophin modulate the immune profile of breast cancer.

Lynn KD, Roland CL, Brekken RA.

Cancers (Basel). 2010 May 26;2(2):970-88. doi: 10.3390/cancers2020970.

13.

Clinical significance of macrophage heterogeneity in human malignant tumors.

Komohara Y, Jinushi M, Takeya M.

Cancer Sci. 2014 Jan;105(1):1-8. doi: 10.1111/cas.12314. Review.

14.

Targeting tumor-infiltrating macrophages to combat cancer.

Panni RZ, Linehan DC, DeNardo DG.

Immunotherapy. 2013 Oct;5(10):1075-87. doi: 10.2217/imt.13.102. Review.

15.

Compartment model predicts VEGF secretion and investigates the effects of VEGF trap in tumor-bearing mice.

Finley SD, Dhar M, Popel AS.

Front Oncol. 2013 Jul 30;3:196. doi: 10.3389/fonc.2013.00196.

16.

VEGF blockade enables oncolytic cancer virotherapy in part by modulating intratumoral myeloid cells.

Currier MA, Eshun FK, Sholl A, Chernoguz A, Crawford K, Divanovic S, Boon L, Goins WF, Frischer JS, Collins MH, Leddon JL, Baird WH, Haseley A, Streby KA, Wang PY, Hendrickson BW, Brekken RA, Kaur B, Hildeman D, Cripe TP.

Mol Ther. 2013 May;21(5):1014-23. doi: 10.1038/mt.2013.39.

17.

Stromal cells in tumor microenvironment and breast cancer.

Mao Y, Keller ET, Garfield DH, Shen K, Wang J.

Cancer Metastasis Rev. 2013 Jun;32(1-2):303-15. doi: 10.1007/s10555-012-9415-3. Review.

18.

Anti-tumour strategies aiming to target tumour-associated macrophages.

Tang X, Mo C, Wang Y, Wei D, Xiao H.

Immunology. 2013 Feb;138(2):93-104. doi: 10.1111/imm.12023. Review.

19.

Expression of Vascular Endothelial Growth Factor correlates with the advance of clinical osteosarcoma.

Lammli J, Fan M, Rosenthal HG, Patni M, Rinehart E, Vergara G, Ablah E, Wooley PH, Lucas G, Yang SY.

Int Orthop. 2012 Nov;36(11):2307-13. doi: 10.1007/s00264-012-1629-z.

20.

IBC's 22nd Annual Antibody Engineering and 9th Annual Antibody Therapeutics International Conferences and the 2011 Annual Meeting of The Antibody Society, December 5-8, 2011, San Diego, CA.

Nilvebrant J, Dunlop DC, Sircar A, Wurch T, Falkowska E, Reichert JM, Helguera G, Piccione EC, Brack S, Berger S.

MAbs. 2012 Mar-Apr;4(2):153-81. doi: 10.4161/mabs.4.2.19495.

Items per page

Supplemental Content

Support Center